Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Abstracts of the 16th International Charles Heidelberger Symposium on Cancer Research

Open Access Poster presentation

Regucalcin, a calcium-binding protein, is a new target gene in human prostate cancer?

Cláudio J Maia, Cátia V Vaz, Carina G Peres, Cecília RA Santos and Sílvia Socorro*

Author Affiliations

Health Sciences Research Centre, Covilhã, Portugal

For all author emails, please log on.

BMC Proceedings 2010, 4(Suppl 2):P13  doi:10.1186/1753-6561-4-S2-P13

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/4/S2/P13


Published:24 September 2010

© 2010 Socorro et al; licensee BioMed Central Ltd.

Poster presentation

Regucalcin was identified as a calcium (Ca2+)-binding protein playing an important role in maintenance of intracellular Ca2+ homeostasis. More recently, proteomic studies have identified it as a down-regulated gene in mouse and human hepatocellular carcinomas. In addition, regucalcin effects in kidney and liver cells, suppressing cell proliferation, inhibiting expression of oncogenes, and increasing the expression of tumor suppressor genes, have been described.

Prostate cancer depends on the trophic effects of androgens, and altered Ca2+ homeostasis and signaling have been associated with the development of this pathology. Therefore, in the present study we analyzed regucalcin expression, in neoplasic and non-neoplasic prostate tissue and cells, by means of RT-PCR, western blot and immunohistochemistry. Regucalcin localizes in cell nuclei and cytoplasm and its expression was diminished in prostate cancer cases. Moreover, regucalcin immunoreactivity was negatively associated with cellular differentiation of prostate adenocarcinoma. The effect of the non-aromatizable androgen 5-alpha-dihydrotestosterone (DHT) on regucalcin expression in vitro, in LNCaP prostate cancer cells, and in vivo, in a rat animal model, was determined. Real-time PCR analysis showed that DHT downregulates regucalcin expression, an effect inhibited in the presence of both flutamide and cyclohexamide, suggesting the involvement of androgen receptor and de novo protein synthesis.

The loss of regucalcin expression in prostate cancer cases and the regulation of its expression by androgens suggest that it may be associated with tumor development and/or progression.